TrialBritish journal of haematology2025

A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study.

Wataru Munakata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.